Developing Anti CD40LG Antibodies to Treat ALS
The immune system plays a key role in the progression of amyotrophic lateral sclerosis (ALS). Anelixis
Therapeutics is developing monoclonal antibodies that block a specific immune system target expressed
on lymphocytes (CD40LG) known to drive neurodegeneration. Anelixis Therapeutics is advancing a lead
candidate AT-1501 into ALS clinical trials in 2018.